key: cord-0988485-3ttgr574 authors: Mahajan, Niraj N.; Srivastava, Shayla; Chakor, Rahul; More, Prajakta; Mahale, Smita D; Gajbhiye, Rahul K. title: Neurological complications of COVID-19 and spontaneous abortion in a pregnant woman - A case reporte date: 2021-06-16 journal: Eur J Obstet Gynecol Reprod Biol DOI: 10.1016/j.ejogrb.2021.06.010 sha: 760cec735a1db96dd0f3f9c3512b64bd804ba933 doc_id: 988485 cord_uid: 3ttgr574 nan We observed that, neurological complications of COVID-19 affecting both the central and peripheral nervous system and skeletal muscles are being increasingly reported [1] . However, to our knowledge, acute neurological complications of COVID-19 are not reported to date. The indirect involvement of the central nervous system (CNS) through viral-mediated immune response, cytokine storm, or autoimmune cross-reactivity between CNS components and viral particles is plausible in addition to the direct viral invasion to CNS [2] . Guillain-Barré syndrome have been reported in other post-viral infections including influenza, Zika, SARS-CoV, MERS-CoV, and SARS-CoV-2 [3] . It was also reported in a pregnant and postpartum woman with COVID-19 [4, 5] . Herein, we report the clinical presentations, management and outcome of SARS-CoV-2 associated Guillain-Barré syndrome in a pregnant woman admitted at BYL Nair Charitable Hospital (NH), a dedicated COVID-19 hospital in Mumbai, India. A 31-years-old G 2 A 1 at her 12 th gestational week with comorbidities of, anemia, rheumatoid arthritis, and old pulmonary tuberculosis was admitted at NH. She had a fever, dry cough, diarrhea, myalgia, and fatigue for the past 5 days. She developed a tingling and pricking sensation over both feet progressing to the knee followed by progressive weakness in her upper and lower limbs within 1 day of symptoms of COVID-19. Over the next four days, her neurological condition worsened, and eventually developed sensory loss up to thigh and elbows and had difficulty walking independently and standing without support. (Table S1-S4) After the IVIG therapy, her single breath counts improved to 22. She responded to antibiotics, heparin, steroid, and hydroxychloroquine. Although her obstetric ultrasonography done at 12 weeks was normal, she aborted spontaneously within 10 days of developing weakness. After 25 days of hospital stay, she took discharge against medical advice. At the time of discharge, she had a mild distal sensory loss in both upper and lower limbs There was mild proximal and distal muscle weakness and she was able to walk independently. The pertinent events in the patient's illness are shown in Figure 1 . We report a rare case of Guillain-Barré syndrome in a pregnant woman with COVID-19 who suffered from spontaneous abortion in the second trimester. To the best of ours knowledge, this is the first reported case of Guillain-Barré syndrome in a confirmed COVID-19 pregnant woman with spontaneous abortion. Out of the total 1572 pregnant and post-partum women with COVID-19, only one patient developed Guillain-Barré syndrome. It is rarely observed in pregnant women and has a very low incidence during pregnancy. A pre-existing comorbid autoimmune disorder such as SLE and APLA, in this case, might be responsible for triggering an acute neurological 4 complication of Guillain-Barré syndrome. However, the mechanism of SARS-CoV-2 triggering Guillain-Barré syndrome is still debated. The immune cross-reaction between epitopes and host antigens could be one of the possible explanations [6] . The interval between the diagnosis of COVID-19 and the onset of Guillain-Barré syndrome symptoms in the present case was one day which was very early than the other reports in the literarature [5, 6] . Uncini and colleagues [6] in their systematic review reported a range from 3 to 28 days. We started the IV IG within 10 days from symptom onset. The regimen of 2g/kg divided over 5 days was given. The patient showed significant improvement and was ambulatory at discharge. To conclude, the presence of autoimmune conditions in pregnancy could be triggering Guillain-Barré syndrome and manifesting early as seen in our case. Based on our results, we recommend that BOH cases and those with a history of confirmed or suspected autoimmune disease with COVID-19 may be investigated specifically for autoimmune neurological diseases. The Ethics Committees of TNMC (No. ECARP/2020/63 dated 27.05.2020) and ICMR-NIRRH (IEC no. D/ICEC/Sci-53/55/2020 dated 04.06.2020) approved the study. A waiver of consent was granted by the IECs as the data was collected from the medical case records of the pregnant women with COVID-19. Written informed consent was obtained from the patient for publication of the Case. A copy of the written consent is available for review by the Editor of this journal. Availability of data and materials 5 The data that supports the findings of this study are available in the supplementary material of this article. No funding. NM and RG had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV-2 and Potential Immunological Mechanisms Guillain-Barré Syndrome in Pregnancy Guillain Barre Syndrome following delivery in a pregnant woman infected with SARS-CoV-2 Intravenous immunoglobulin in COVID-19 associated Guillain-Barré syndrome in pregnancy Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic